Biogen points to COVID-19 for disappointing drug launch

After six months on the market, Biogen's new pill for multiple sclerosis hasn't performed as well as the company hoped.

Sold as Vumerity, the pill is supposed to be an improvement over Biogen's top drug Tecfidera, revenue from which totaled almost $2.3 billion during the first half of the year. But according to company leadership, the coronavirus pandemic created an obstacle that's been hard for Vumerity to overcome.